Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

NCT06751901 ·Status: RECRUITING ·Phase: PHASE2

Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

NCT05991180 ·Status: RECRUITING

Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer

NCT04945200 ·Status: UNKNOWN

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

NCT04857164 ·Status: RECRUITING ·Phase: PHASE2

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

NCT04740996 ·Status: UNKNOWN

Anlotinib Therapy in Patients With Advanced Lung Cancer.

NCT03940404 ·Status: UNKNOWN

Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer

NCT05387512 ·Status: COMPLETED

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

NCT06341530 ·Status: RECRUITING ·Phase: PHASE2

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

NCT05004974 ·Status: RECRUITING ·Phase: PHASE2

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

NCT06752044 ·Status: RECRUITING ·Phase: NA

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

NCT05577702 ·Status: COMPLETED ·Phase: PHASE2

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

NCT02577341 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

NCT05136677 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors

NCT05134948 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

NCT05129202 ·Status: COMPLETED

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

NCT04612673 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

NCT03195478 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

NCT05319574 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study

NCT05719324 ·Status: UNKNOWN

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC

NCT06718309 ·Status: RECRUITING ·Phase: PHASE2

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

NCT07005336 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC

NCT04167774 ·Status: UNKNOWN ·Phase: PHASE2

The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients

NCT06496009 ·Status: NOT_YET_RECRUITING

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

NCT05974007 ·Status: RECRUITING

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

NCT05980702 ·Status: RECRUITING ·Phase: PHASE2